FDA Grants 510(k) Clearance for Abiomed’s Innovative Cardiopulmonary Support Technology
The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005299/en/
The Abiomed Breethe OXY-1 System has received 510(k) clearance from the United States FDA (Photo: Buisness Wire)
The ECMO system provides cardiopulmonary bypass support for patients whose lungs can no longer provide sufficient end organ oxygenation. The 510(k) clearance is to pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass for up to six hours. The system can help provide oxygenation to patients suffering from cardiogenic shock or respiratory failure such as ARDS, H1N1, SARS, or COVID-19. When used with the Impella heart pump it can unload the heart and oxygenate the body, a combination therapy known as ECpella.
Abiomed’s Breethe technology is a novel, easy-to-use cardiopulmonary bypass system that is designed for mobility. The components of the system are designed to reduce the overall equipment footprint, support patient ambulation, and provide an intuitive interface for health care providers to setup and manage. The integrated pump lung unit is engineered with volute spiral technology for uniform blood flow with minimal stagnation and advanced gas exchange technology that allows for full therapy with reduced oxygen requirements.
“As a leader in technology and innovation, the Breethe system is a natural addition to Abiomed’s existing product portfolio,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “This ECMO technology will allow us to support new patient populations, such as COVID-19 patients and others who need lung support, and provide combination ECpella therapy to Impella patients who need oxygenation. Furthermore, we will advance the field of native lung recovery and improve patient outcomes by collecting critical research data and developing and teaching best practices.”
“Abiomed has a long-established track record of bringing to market improved options to support physicians with innovative technology like Breethe, which is designed to provide advanced respiratory and cardiac support,” said Bartley Griffith, MD, the Hales Distinguished Professor of Surgery at University of Maryland, School of Medicine. “Abiomed is committed to advancing heart and lung therapies to help improve patient care and ultimately outcomes.”
“The clinical community has long been in need of innovation compared to traditional extracorporeal circulation therapy,” said Dr. Zachary Kon, cardiothoracic surgeon at New York University. “The Breethe system is a breakthrough technology because it supports transition from bed to ambulation via system portability. This system has the potential to revolutionize the way we think about extracorporeal life support therapy and can improve patient care.”
To help health care providers achieve the best possible outcomes, the Breethe system will be supported 24 hours a day, 7 days a week by Abiomed’s experienced field-based, in-hospital clinical team and on-call team from the Clinical Support Center.
This ECMO technology adds to Abiomed’s innovative portfolio focused on native heart and lung recovery. For many patients in cardiogenic shock, Abiomed now provides the treatment options of both the catheter-based Impella heart pump, which unloads the left ventricle, perfuses end organs and allows the heart to rest and recover, and Breethe, which provides oxygenation. Impella and Breethe can work together as ECpella to unload the heart and oxygenate the body.
Multiple studies support the association of ECpella therapy to improve outcomes for patients who are suffering from cardiogenic shock and require oxygenation. A study published this month in Circulation examined data from 686 consecutive patients at 16 tertiary-care centers from four countries and found ECpella was associated with increased 30-day survival (43% vs 37%; p=0.03). The European Journal of Heart Failure, ASAIO, and the Journal of the American College of Cardiology have published studies that conclude use of ECpella was associated with increased survival rates, as compared to patients who were treated with ECMO only. This benefit is not seen in patients treated with ECMO combined with the intra-aortic balloon pump (IABP). (see figure 1) Additionally, the study in the European Journal of Heart Failure found higher rates of heart recovery with ECpella use than with ECMO only (62% vs 36%; p=0.048).
In August, the FDA issued an emergency use authorization (EUA) for all left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis.
Abiomed plans to have a controlled launch of the Breethe system at hospitals in the United States, with full U.S. commercial availability expected in calendar year 2021.
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
ABOUT ABIOMED BREETHE OXY-1 SYSTEM
The Abiomed Breethe OXY-1 System™ is cleared by the U.S. Food and Drug Administration (FDA) to provide extracorporeal circulation. The OXY-1 System pumps, oxygenates and removes carbon dioxide from blood during cardiopulmonary bypass up to six (6) hours in duration.
Under guidance issued by FDA, on April 6, 2020, the Abiomed Breethe OXY-1 System is now permitted to be used temporarily in the U.S. for ECMO therapy greater than six hours. Therefore, it now has a limited indication modification for use longer than six hours in an extracorporeal membrane oxygenation (ECMO) circuit to treat patients who are experiencing acute temporary respiratory or acute cardiopulmonary failure. This limited indication modification for ECMO therapy greater than six hours has not been cleared or approved by FDA and is in effect only for the duration of the public health emergency related to COVID-19 as declared by the U.S. Department of Health and Human Services (HHS).
ABOUT IMPELLA HEART PUMPS
The Impella 2.5®, Impella CP®, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella Left Ventricular (LV) Support Systems are also authorized for emergency use by HCPs in the hospital setting for providing temporary (≤ 4 days for Impella 2.5, Impella CP, and Impella CP with SmartAssist; and ≤ 14 days for Impella 5.0 and Impella 5.5 with SmartAssist) LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support. The authorized Impella LV Support Systems have neither been cleared or approved for the authorized indication for use. The Impella RP and Impella LV Support Systems have been authorized for the above emergency use by FDA under an EUA and have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Director of Communication
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Q4 Helps Public Companies and Investment Firms Keep Their Teams Aligned and Informed28.7.2021 16:00:00 EEST | Press release
Q4 Inc. announced today it is applying its unique expertise in delivering mission-critical virtual events to help public companies, buy-side and sell-side firms build transparency, trust and excitement across a widely dispersed workforce. With the seismic shift in working models giving employees increasing flexibility to work both in remote or hybrid setups, maintaining a strong internal communications platform to globally distributed teams is vital for companies across all industries. Simultaneously, the commitment to providing a sustainable work environment and strong corporate culture continues to intensify as companies seek to implement successful ESG policies and programs. Q4’s new Corporate Town Hall subscriptions combine technology and a premium end-to-end service model to help its capital markets clients communicate strategy and best practices, provide quarterly business reviews, host sales kick-offs, and ultimately foster the inclusive culture they have worked so hard to devel
ZS Elects Pratap Khedkar to CEO28.7.2021 16:00:00 EEST | Press release
Global professional services firm ZS today announced that Pratap Khedkar, head of the firm’s global biopharmaceuticals and healthcare ecosystem practices, has been elected to CEO by the firm’s leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005232/en/ Pratap Khedkar, CEO, ZS (Photo: Business Wire) Khedkar is the third CEO in ZS’s nearly 40-year history. He was elected by his peers, a structure ZS’s founders Andris A. Zoltners and Prabhakant Sinha established to ensure cultural continuity and to elevate leaders who embody the company’s dedication to strategy, innovation and client collaboration. He succeeds Chris Wright, who served the firm’s maximum term and will be affiliated with ZS for the next five years as part of its principal emeritus program, focusing on the projects that he’s most passionate about. Khedkar has held various leadership roles during his 21 years with ZS. Khedkar has led the firm’s global
Dixa, the Next-Gen CX Platform, Raises $105M Series C to Transform Customer Service Worldwide28.7.2021 15:30:00 EEST | Press release
Founded as a customer service solution that evolved into a customer engagement platform, European company Dixa today announced a Series C funding round totaling $105M. The company is leading the change from customer service to value creation with a multiexperience approach, challenging the status quo and delivering value-driven experiences that generate results for businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728005430/en/ Dixa Founding Team (Photo: Business Wire) The Series C round is led by General Atlantic, a leading global growth equity investor with a history of backing and scaling companies that transformed their industries, with participation from existing investors Notion Capital Project A and Seed Capital. Dixa will leverage the new funds to invest in product development, including potential new acquisitions (following Dixa’s acquisition of Melbourne-based Elevio in January 2021), and plans to quadr
V.E, Part of Moody’s ESG Solutions, Provides Second Party Opinion on the Kingdom of Spain’s Sovereign Green Bond Framework28.7.2021 15:30:00 EEST | Press release
Moody’s ESG Solutions Group announced today that V.E has provided a Second Party Opinion (SPO) on the Kingdom of Spain’s Sovereign Green Bond Framework. The Framework is aligned with the four core components of the Green Bond Principles 2021 and follows best market practices identified by V.E. Net proceeds of the bonds will exclusively be used to finance or refinance projects tied to the country’s environmental objectives, including renewable energy, biodiversity protection, and climate change adaptation. “The bonds issued under Spain’s Framework will provide an ‘advanced’ contribution to sustainability, the highest score on our four-point scale,” said Patrick Mispagel, MD – Sustainable Finance at Moody’s ESG Solutions. “Our assessment reflects that in many cases Spain’s Framework followed the detailed technical eligibility criteria of the EU Taxonomy Climate Delegated Act. We expect to see additional sovereign issuances as nations increasingly seek to raise capital to support climate
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)28.7.2021 15:15:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1),2 a chronic neurological disorder that alters the sleep-wake cycle.3 EDS is a hallmark symptom of NT1 and is characterized by a person’s inability to stay awake and alert throughout the day, and falling asleep unintentionally or at inappropriate times on a daily basis.3,4 The FDA’s Breakthrough Therapy Designation process is designed to expedite the development and review of a drug that is intended to treat a serious condition, for which preliminary clinical evidence exists indicating it may demonstrate a substantial improvement over available therapies on at
BlueConic is the First Customer Data Platform to Offer a Data Clean Room Solution28.7.2021 15:02:00 EEST | Press release
Driven by the death of the third-party cookie and its debilitating impact on the digital advertising industry, data clean rooms are growing in popularity among brands and publishers alike. To meet this demand, BlueConic is proud to announce its own comprehensive data clean room solution, making it the first customer data platform (CDP) to do so. The move will enable its customer base of over 300 companies worldwide to facilitate second-party data sharing in a privacy-safe environment. The solution provides brands and publishers with a privacy-compliant way to combat the effects of Apple and Google’s decisions to deprecate the use of third-party cookies in their respective web browsers, Safari and Chrome. Without such a solution, marketers will lose the ability to measure the impact of digital advertising spend once and for all. Industry analysts agree that BlueConic is uniquely poised to offer such a solution. Unlike other data clean rooms on the market, BlueConic’s solution will: Insu
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis28.7.2021 15:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company will initiate a Phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor) in the second half of 2021. The combination of VX-121/tezacaftor/VX-561 was first identified as having potential for increased efficacy based on its ability to drive higher levels of chloride transport compared to TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in human bronchial epithelial cells in vitro. The combination of VX-121/tezacaftor/VX-561 was evaluated in a Phase 2 study in people with cystic fibrosis (CF) ages 18 and older with one F508del mutation and one minimal function mutation (F/MF) and in people with CF ages 18 and older with two F508del mutations (F/F). The regimen was generally well-tolerated, and the study met the primary efficacy endpoint of absolute change from baseline in ppFEV1 and all secondary efficacy endpoints including abso
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom